# A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

> **NCT07710768** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 44 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** UBT251
- **DRUG:** Cocktail (Warfarin/Caffeine/Midazolam)

## Key facts

- **NCT ID:** NCT07710768
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-04-07
- **Final completion:** 2027-04-07
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710768, "A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07710768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*